Driving Maximum Efficiency with Expanded PAT Capabilities & Solutions

Repligen Acquires 908 Devices’ Bioprocessing PAT Portfolio

Repligen is pleased to announce the acquisition of 908 Devices’ bioprocessing Process Analytical Technology (PAT) portfolio. This strategic move strengthens our commitment to delivering best-in-class real-time analytics, PAT-driven insights, and next-generation tools for bioprocessing development and manufacturing.

These innovative products, designed to provide critical upstream process insights, complement Repligen’s existing Process Analytical Technology (PAT) portfolio for downstream applications.

By integrating these capabilities, we enhance end-to-end process visibility, enable more seamless control, and drive greater efficiency across the entire bioprocessing workflow.

Read the Press Release

For Cell Culture Media Analysis

REBEL

Analyze fresh or spent media and get quantitative reports for amino acids, dipeptides, water soluble vitamins and biogenic amines.
For Bioprocessing

MAVERICK

Raman-based, in-line monitoring and control of key bioprocessing parameters across up to six bioreactors simultaneously.
For Glucose & Lactate

MAVEN

Real-time glucose and lactate monitoring provides valuable insights and control without compromising bioreactor or fermenter volume.
For Biological Characterization

ZipChip

Rapid protein characterization for efficient, accurate, and comprehensive analysis of multiple CQAs.

Frequently Asked Questions

General Sale & Ownership Questions

This transition benefits customers by providing a dedicated focus on bioprocessing analytical solutions, supported by a larger R&D, Service, and Sales team. With Repligen’s extensive expertise, customers will gain access to a more integrated and innovative approach to bioprocessing solutions, driving efficiency and scalability in workflows.

Repligen, a leader in bioprocessing innovation, is the new owner of this portfolio. Known for its commitment to driving advanced workflows, Repligen is dedicated to finding better ways to develop and manufacture therapies across multiple modalities.

We are beginning the process of integrating the 908 Devices portfolio into Repligen. However, this transition will take time. For now, there are no immediate changes—customers should continue working with their existing 908 Devices representatives as usual. We will notify you well in advance of any changes.

Yes. By integrating the 908 Devices portfolio into the Repligen Process Analytics portfolio, we aim to better address the unmet needs of bioprocessing customers. Bringing together engineering experts across various analytical measurement technologies will drive further innovation and deliver enhanced solutions.
PRODUCT SUPPORT & SERVICE

No. All existing service contracts and warranties will remain in effect under their current terms for the duration of their agreement.

For now, please continue reaching out to your current 908 Devices support team. We are planning the transition carefully to minimize disruptions, and both companies will work together to guide you through the process.

Yes. All replacement parts and consumables will remain available through the existing 908 Devices ordering process. Customers will be notified in advance if there are any changes to ordering procedures.

Yes. Repligen is committed to driving improvement and innovation. Software optimization will continue with a broader team of Process Analytical Technology software experts, ensuring compatibility and seamless workflow integration.

As we work through the transition of the portfolio to Repligen.com, all product information and support documents can still be found on the 908 Devices website (https://908devices.com/). As we try to minimize any disruption to your daily business, we will work closely with 908 Devices to ensure a smooth transition of content and supporting documents onto Repligen.com.
ORDERING & PROCUREMENT

For now, all ordering processes remain the same. Customers should continue to place orders through their existing 908 Devices channels. Any future changes will be communicated well in advance.

Initially, there will be no changes—customers should continue working with their current 908 Devices representatives. If there are any future adjustments, we will provide timely updates.

All existing purchase orders will be honored under the agreed terms with 908 Devices. There is no need to reissue them at this time.

We are working to ensure a smooth transition with minimal disruption to order fulfillment. If any changes to lead times occur, customers will be notified as early as possible.

Yes. Customers should continue to request these services through their existing 908 Devices contacts as they have been. Once the transition is complete, these services will continue to be available through the Repligen Service & Support team. We will notify customers in advance of any changes to the process to ensure a smooth transition.

Absolutely. Repligen is dedicated to maintaining the highest quality standards, and this acquisition strengthens our ability to deliver robust, compliant analytical solutions.
FUTURE PRODUCT ROADMAP & INNOVATION

Yes. Repligen is committed to continuous innovation. With a dedicated focus on Process Analytical Technology, we plan to enhance the portfolio and deliver even more advanced solutions to bioprocessing customers.

There are no immediate plans for discontinuations. Future enhancements will be driven by customer needs and Repligen’s ongoing commitment to innovation.

Need Additional Support?

We’re here to assist you throughout this transition. If you have questions about the recent acquisition or need product support but aren’t sure who to contact, please complete this form, and a representative will reach out to help.